| Citation: |
XU Xin-zhi, YANG Ji. Advances in diagnosis and treatment of cutaneous adverse events associated with tumor targeted drugs and immune checkpoint inhibitors[J]. Chin J Clin Med, 2021, 28(6): 943-947. DOI: 10.12025/j.issn.1008-6358.2021.20210559
|
Tumor targeted therapy and immunotherapy are important advances in tumor treatment. With numerous varieties and promising efficacy, targeted drugs and immune checkpoint inhibitors are widely used in clinical practice, which meanwhile triggers a series of adverse events. Among them, cutaneous adverse events are more common. Skin diseases caused by different drugs are distinct, and treatment varies from person to person. Although cutaneous adverse events associated with tumor treatment affect the physical and psychological health of patients, they may indicate better therapeutic effect.
| [1] |
喻敏成, 胡博, 付佩尧, 等. 抗PD-1/PD-L1抗体临床治疗不良反应研究进展[J]. 中国临床医学, 2018, 25(4): 625-631. http://www.c-jcm.com/zglcyx/ch/reader/view_abstract.aspx?file_no=20180320&flag=1
YU M C, HU B, FU P Y, et al. Research progress on adverse events in clinical treatment of anti-PD-1/PD-L1 antibodies[J]. Chinese Journal of Clinical Medicine, 2018, 25(4): 625-631. http://www.c-jcm.com/zglcyx/ch/reader/view_abstract.aspx?file_no=20180320&flag=1
|
| [2] |
REYES-HABITO C M, ROH E K. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer[J]. J Am Acad Dermatol, 2014, 71(2): 211-217.
|
| [3] |
HOLCMANN M, SIBILIA M. Mechanisms underlying skin disorders induced by EGFR inhibitors[J]. Mol Cell Oncol, 2015, 2(4): e1004969. DOI: 10.1080/23723556.2015.1004969
|
| [4] |
MONJAZEB S, WILSON J. Epidermal growth factor receptor inhibitors: cutaneous side effects and their management[J]. Skin Therapy Lett, 2017, 22(5): 5-7.
|
| [5] |
MACDONALD J B, MACDONALD B, GOLITZ L E, et al. Cutaneous adverse effects of targeted therapies Part Ⅰ: inhibitors of the cellular membrane[J]. J Am Acad Dermatol, 2015, 72(2): 203-218. DOI: 10.1016/j.jaad.2014.07.032
|
| [6] |
YALICI-ARMAGAN B, AYANOGLU B T, DEMIRDAG H G. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study[J]. Cutan Ocul Toxicol, 2019, 38(3): 261-266. DOI: 10.1080/15569527.2019.1594874
|
| [7] |
LACOUTURE M, SIBAUD V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails[J]. Am J Clin Dermatol, 2018, 19(Suppl 1): 31-39.
|
| [8] |
VALENTINE J, BELUM V R, DURAN J, et al. Incidence and risk of xerosis with targeted anticancer therapies[J]. J Am Acad Dermatol, 2015, 72(4): 656-667. DOI: 10.1016/j.jaad.2014.12.010
|
| [9] |
LI Y W, FENG H, REN P, et al. Safety and efficacy of apatinib monotherapy for unresectable, metastatic esophageal cancer: a single-arm, open-label, phase Ⅱ study[J]. Oncologist, 2020, 25(10): e1464-e1472. DOI: 10.1634/theoncologist.2020-0310
|
| [10] |
INAMOTO T, AZUMA H, TATSUGAMI K, et al. Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan[J]. Expert Rev Anticancer Ther, 2020, 20(7): 615-623. DOI: 10.1080/14737140.2020.1773805
|
| [11] |
ABDEL-RAHMAN O, FOUAD M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis[J]. Expert Rev Anticancer Ther, 2015, 15(1): 129-141. DOI: 10.1586/14737140.2015.985660
|
| [12] |
BELUM V R, SERNA-TAMAYO C, WU S, et al. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis[J]. Clin Exp Dermatol, 2016, 41(1): 8-15. DOI: 10.1111/ced.12694
|
| [13] |
CORTES J E, KIM D W, PINILLA-IBARZ J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial[J]. Blood, 2018, 132(4): 393-404. DOI: 10.1182/blood-2016-09-739086
|
| [14] |
GNANENDRAN S S, TURNER L M, MILLER J A, et al. Cutaneous adverse events of anti-PD-1 therapy and BRAF inhibitors[J]. Curr Treat Options Oncol, 2020, 21(4): 29. DOI: 10.1007/s11864-020-0721-7
|
| [15] |
EIGENTLER T K, HASSEL J C, BERKING C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016, 45: 7-18. DOI: 10.1016/j.ctrv.2016.02.003
|
| [16] |
SIBAUD V. Dermatologic reactions to immune checkpoint inhibitors skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018, 19(3): 345-361. DOI: 10.1007/s40257-017-0336-3
|
| [17] |
LI J, GU J. Rash and pruritus with PD-1 inhibitors in cancer patients: a meta-analysis of randomized controlled trials[J]. J Clin Pharmacol, 2019, 59(1): 45-54. DOI: 10.1002/jcph.1291
|
| [18] |
ABDEL-RAHMAN O, ELHALAWANI H, FOUAD M, et al. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis[J]. Future Oncol, 2015, 11(17): 2471-2484. DOI: 10.2217/fon.15.118
|
| [19] |
SCHABERG K B, NOVOA R A, WAKELEE H A, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy[J]. J Cutan Pathol, 2016, 43(4): 339-346. DOI: 10.1111/cup.12666
|
| [20] |
MARANO A L, CLARKE J M, MORSE M A, et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death (PD)-1 therapy[J]. Br J Dermatol, 2018, 181(3): 580-583.
|
| [21] |
NGUYẼN T, MARIA A T J, LADHARI C, et al. Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis?An analysis of the WHO's adverse drug reactions database[J]. Ann Rheum Dis, 2020: 217018.
|
| [22] |
KATO Y, OTSUKA A, MIYACHI Y, et al. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma[J]. J Eur Acad Dermatol Venereol, 2016, 30(10): e89-e91. DOI: 10.1111/jdv.13336
|
| [23] |
MURATA S, KANEKO S, HARADA Y, et al. Case of de novo psoriasis possibly triggered by nivolumab[J]. J Dermatol, 2017, 44(1): 99-100. DOI: 10.1111/1346-8138.13450
|
| [24] |
GIROLOMONI G, STROHAL R, PUIG L, et al. The role of IL-23 and the IL-23/Th 17 immune axis in the pathogenesis and treatment of psoriasis[J]. J Eur Acad Dermatol Venereol, 2017, 31(10): 1616-1626. DOI: 10.1111/jdv.14433
|
| [25] |
ALEXANDRE GÉRARD, DOYEN J, CREMONI M, et al. Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients[J]. J Immunother Cancer, 2021, 9(6): e002512. DOI: 10.1136/jitc-2021-002512
|
| [26] |
ANNUNZIATA M C, DE STEFANO A, FABBROCINI G, et al. Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer[J]. Clin Drug Investig, 2019, 39(9): 825-834. DOI: 10.1007/s40261-019-00811-7
|
| [27] |
CURY-MARTINS J, ERIS A P M, ABDALLA C M Z, et al. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel[J]. An Bras Dermatol, 2020, 95(2): 221-237. DOI: 10.1016/j.abd.2020.01.001
|
| [28] |
PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1): 95. DOI: 10.1186/s40425-017-0300-z
|
| [29] |
RZEPECKI A K, CHENG H Y, MCLELLAN B N. Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy[J]. J Am Acad Dermatol, 2018, 79(3): 545-555. DOI: 10.1016/j.jaad.2018.04.046
|
DownLoad: